Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8016874 | 0.89 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KDM4ECYP3A4 | |
| SCHEMBL31265560 | 0.89 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KDM4ECYP3A4 | |
| Water SCHEMBL5700740 | 0.84 | GABRA1 (0.55) | MAPTGABRA1GABRB2ALDH1A1 | |
| SCHEMBL906143 | 0.82 | TSHR (0.52) | KDM4EGABRA1GABRB2ALDH1A1PKM | |
| SCHEMBL9512782 | 0.81 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3KDM4ECYP3A4 | |
| SCHEMBL25425763 | 0.81 | GABRA1 (0.58) | MAPTGABRA1GABRB2ALDH1A1 | |
| SCHEMBL29390847 | 0.81 | GABRA1 (0.58) | MAPTGABRA1GABRB2ALDH1A1 | |
| SCHEMBL36294 | 0.81 | GABRA1 (0.58) | MAPTGABRA1GABRB2ALDH1A1 | |
| SCHEMBL23898743 | 0.80 | GABRA1 (0.42) | MAPTGABRA1GABRB2ALDH1A1 | |
| SCHEMBL21254118 | 0.79 | GABRA1 (0.43) | SLC6A4SLC6A2SLC6A3KDM4ECYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1882000-B1 | CATALYST COMPOSITION FOR OLEFIN POLYMERIZATION | NOVOLEN TECH HOLDINGS CV (NL) | 2010-03-31 | — | — | EP | claimed |
| WO-2023125737-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF | SILEXON AI TECHNOLOGY CO., LTD. (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2022-06-02 | — | — | US | disclosed |
| WO-2022040600-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
| EP-3086815-B1 | SULFONAMIDE-CONTAINING LINKAGE SYSTEMS FOR DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021197283-A1 | SYNTHETIC PEPTIDE AMIDE COMPOUND AND ITS USE IN THE FIELD OF MEDICINE | CHENGDU SINTANOVO BIOTECHNOLOGY CO., LTD. (CN) | 2021-10-07 | — | — | WO | disclosed |
| EP-3558973-B1 | PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021072203-A1 | TGFBETAR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| EP-3558989-B1 | TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS IMMUNOMODULATORS | INCYTE CORP (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-02-09 | — | — | US | disclosed |
| CN-101193895-A | Method for producing tricyclic ketone | YAKULT HONSHA KK (JP) | 2008-06-04 | — | — | CN | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2007-05-24 | — | — | US | disclosed |
| EP-1250363-B1 | CHEMICAL COMPOUND, METHOD FOR THE PRODUCTION THEREOF AND ITS USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1615698-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| EP-1280600-B1 | SUPPORTED CATALYST SYSTEM COMPRISING A METALLOCENE, A LEWIS-BASE AND AN ORGANODEMENTAL COMPOUND OF MAIN GROUP III, AND ITS USE | BASELL POLYOLEFINE GMBH (DE) | 2004-08-11 | — | — | EP | disclosed |
| EP-1290002-B1 | CHEMICAL PRODUCTS SUITED FOR USE AS CO-CATALYSTS, METHOD FOR THE PREPARATION THEREOF AND THEIR USE IN CATALYST SYSTEMS FOR PRODUCING POLYOLEFINS | BASELL POLYOLEFINE GMBH (DE) | 2004-01-21 | — | — | EP | disclosed |
| EP-0362001-A1 | N-cycloalkyl benzylamines alpha,alpha disubstituted, the process for their preparation, their use as drugs and their synthesis intermediates | JOUVEINAL S.A. (FR) | 1990-04-04 | — | — | EP | disclosed |
| US-4604472-A | ANTICHOLESTEROL AGENTS | SANKYO COMPANY LIMITED (JP) | 1986-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117154-A1 | Cyclic lactams comprising three amino acids and a tether chain to control the overall shape of the macromolecule; beta-turn mimetics to explore conformationally restricted structures; proteolytic enzyme resistance (nonhydrolyzing); cell penetration; anticoagulants; anticarcinogenic agents | F2, BCAT1, DAO | SLC6A4 4470/4885SLC6A2 4673/4885SLC6A3 4822/4885 |
| US-20220168383-A1 | NEUROTENSINERGIC AGONISTS AND METHODS OF USING SAME PREVENTING OR TREATING PAIN | VIP, NTSR2, VIPR2 | SLC6A4 272/4885SLC6A2 220/4885SLC6A3 567/4885 |
| US-10913738-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | SLC6A4 3049/4885SLC6A2 4399/4885SLC6A3 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.